Location of Repository

Preclinical Studies of 3',4',5'-Trimethoxyflavonol, a Putative Agent for the Chemoprevention and the Management of Prostate Cancer

By Shaban Eljali Ali Saad


Flavonoids have shown much promise for the chemoprevention of PCa but their poor bioavailability is thought to hinder their chemopreventive efficacy in vivo. However, methoxylation of the flavonoid scaffold could improve bioavailability and efficacy. 3’,4’,5’-trimethoxyflavonol (TMFol) was identified as the most potent growth-inhibitory agent against the PCa cell lines tested. TMFol was 5-15 times more growth inhibitory than fisetin and quercetin, two widely studied flavonols. \ud TMFol caused a G2/M arrest in androgen-dependent cells (LNCaP and TRAMP C2) whereas S phase arrest in the androgen-independent cells (PC-3). TMFol induced more apoptosis in the androgen-dependent cells than the androgen-independent one TMFol inhibited the expression and activity of the AR and also repressed the mRNA levels of both AR and PSA. TMFol also modulated a number of key apoptotic proteins. In vitro data suggests that TMFol may modulate similar proteins to that of quercetin and fisetin, however, exerting its activity at much lower concentrations. Pharmacokinetic data revealed that TMFol levels achievable in the prostate tissue were higher than the concentrations required in vitro to exert pharmacological activity. \ud Nude mice were administered either control diet or diet supplemented with 0.2% w/w TMFol one week prior to cell inoculation. TRAMP C2 cells were implanted into the right flanks of the mice and tumours, once established, were measured twice a week. TMFol significantly reduced the size and weight of the tumour versus control (p<0.05). Equimolar concentrations of quercetin and fisetin in the same model failed to exert efficacy. The expression of p27, bax and survivin which were significantly altered in vitro were also significantly changed following TMFol intervention. These results further our understanding of the in vitro and in vivo pharmacology and cancer preventative activity of TMFol and provide evidence that TMFol may be investigated in preference to quercetin or fisetin for the management of PCa

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/10067

Suggested articles



  1. (2010). (TMFol), a novel putative prostate cancer chemopreventive agent:
  2. (2006). [The roles of c-Jun and CBP in the inhibitory effect of quercetin on prostate cancer cells].
  3. (2008). 20(S)-25-methoxyl-dammarane-3 beta,12 beta,20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.
  4. (2010). 3', 4', 5'-Trimethoxyflavonol (TMFol), a novel putative prostate cancer chemopreventive agent: in vitro and in vivo preclinical efficacy. The 50th Anniversary meeting of The British Association for Cancer Research,
  5. (2003). 5 alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
  6. (2010). 5-alpha-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.
  7. (2008). A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
  8. (2002). A novel targeting modality to enhance adenoviral replication by vitamin D-3 in androgen-independent human prostate cancer cells and tumors.
  9. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
  10. (2002). A population-based study of daily nonsteroidal antiinflammatory drug use and prostate cancer. Mayo Clinic Proceedings,
  11. (1997). A prevalent missense substitution that modulates activity of prostatic steroid 5 alpha-reductase.
  12. (2007). A review of phase III clinical trials of prostate cancer chemoprevention.
  13. (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF.
  14. (2003). A systematic review and meta-analysis of familial prostate cancer risk.
  15. (2010). A Western-Type Diet Accelerates Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer.
  16. (2005). Absorption and enterohepatic circulation of baicalin in rats.
  17. (2004). Absorption and metabolism of flavonoids.
  18. (1998). Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues.
  19. (2007). Advances in the treatment of prostate cancer.
  20. (2011). Adverse Side Effects of 5 alpha-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients.
  21. (1996). Age and racial distribution of prostatic intraepithelial neoplasia.
  22. Alcohol consumption and prostate cancer risk: Results from the Melbourne collaborative cohort study.
  23. (2001). Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study.
  24. (2004). Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study.
  25. (2008). alpha-reductase expression in the development and progression of prostate cancer.
  26. (2004). Alterations of androgen receptor in prostate cancer.
  27. (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
  28. (2004). An IAP-IAP complex inhibits apoptosis.
  29. (2006). Androgen and its receptor promote Bax-mediated apoptosis.
  30. (2008). Androgen and prostate cancer: is the hypothesis dead?
  31. (2005). Androgen deprivation therapy for prostate cancer.
  32. (2002). Androgen receptor (AR) coregulators: An overview.
  33. (2003). Androgen receptor and prostate cancer: Molecular aspects and gene expression profiling.
  34. (2004). Androgen receptor cross-talk with cell signalling pathways.
  35. (2002). Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells.
  36. (1996). Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.
  37. (1997). Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
  38. (2003). Androgen receptor isoforms AR-A and AR-B display functional differences in cultured human bone cells and genital skin fibroblasts.
  39. (2011). Androgen receptor levels are upregulated by Akt in prostate cancer.
  40. (2004). Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells.
  41. (2004). Androgen receptor outwits prostate cancer drugs.
  42. (2010). Androgen receptor signaling and mutations in prostate cancer.
  43. (2008). Androgen receptor signalling in prostate: Effects of stromal factors on normal and cancer stem cells. Molecular and Cellular Endocrinology,
  44. (2007). Androgen receptor structural and functional elements: Role and regulation in prostate cancer.
  45. (2002). Androgen receptors in prostate cancer.
  46. (1999). Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter.
  47. (2002). Androgen-mediated resistance to apoptosis.
  48. (2003). Animal models of bone metastasis.
  49. (2000). Antiandrogen withdrawal syndrome associated with prostate cancer therapies - Incidence and clinical significance.
  50. (2000). Antioxidants and cancer, part 3: quercetin.
  51. (2009). APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the Apc(Min) mouse model in vivo.
  52. (2008). Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med.
  53. (2004). Apoptosis as a novel target for cancer chemoprevention.
  54. (2010). Apoptosis by dietary agents for prevention and treatment of prostate cancer.
  55. (2008). Apoptosis in normal and cancer stem cells. Critical Reviews in Oncology Hematology,
  56. (2000). Apoptosis signaling.
  57. (2005). Applied Biopharmaceutics & Pharmacokinetics,
  58. (2008). AR, the cell cycle, and prostate cancer.
  59. (2008). Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin.
  60. (2001). Bcl-2-/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer.
  61. (1998). bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.
  62. (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
  63. (2005). Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.
  64. (2005). Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies.
  65. (2005). Bioavailability and metabolic pharmacokinetics of rutin and quercetin in rats.
  66. (2010). Bioavailability Challenges Associated with Development of Anti-Cancer Phenolics.
  67. (2010). Bioavailability of dietary flavonoids and phenolic compounds.
  68. (2009). Bioavailability of Flavonoids: A Review of Their Membrane Transport and the Function of Bilitranslocase in Animal and Plant Organisms.
  69. (2007). Bioavailable flavonoids: Cytochrome P450-mediated metabolism of methoxyflavones.
  70. (2005). Blackberry anthocyanins are mainly recovered from urine as methylated and glucuronidated conjugates in humans.
  71. (2007). Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice.
  72. (1989). BPH epidemiology and risk factors.
  73. (2010). Calcium Intake Increases Risk of Prostate Cancer among Singapore Chinese.
  74. (2008). Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways.
  75. (2008). Cancer chemoprevention: a summary of the current evidence.
  76. (2007). Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones.
  77. (2006). Cancer incidence in a cohort of Finnish male smokers.
  78. (2009). Cancer Prevention and Treatment with Resveratrol: From Rodent Studies to Clinical Trials.
  79. (2002). Cancer prevention science and practice.
  80. (2003). Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program.
  81. (1999). CDK inhibitors: positive and negative regulators of G(1)-phase progression.
  82. (1997). Cellular functions regulated by Src family kinases.
  83. (2003). Cellular uptake and efflux of the tea flavonoid (-)-epicatechin-3-gallate in the human intestinal cell line Caco-2.
  84. (2004). Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity.
  85. (2000). Cellular uptake of dietary flavonoid quercetin 4 '-beta-glucoside by sodium-dependent glucose transporter SGLT1.
  86. (1999). Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer.
  87. (2005). Challenges in prostate cancer research: Animal models for nutritional studies of chemoprevention and disease progression.
  88. (2004). Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
  89. (2000). Changes in immune function with age.
  90. (2000). Chapter 2: The role of steroid hormones in prostate carcinogenesis.
  91. (1997). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
  92. (2007). Characterizing spatial and environmental determinants of prostate cancer using a geographic information system.
  93. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial.
  94. (2007). Chemoprevention of prostate cancer through dietary agents: progress and promise.
  95. (2002). Chemoprevention of prostate cancer: Current status and future directions.
  96. (2009). Chemoprevention of prostate cancer: what can be recommended to patients? Curr Urol Rep,
  97. (2006). Chemoprevention of prostate cancer.
  98. (1991). Chemotaxonomy of the Genus Citrus Based on Polymethoxyflavones.
  99. (2007). Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.
  100. (2006). Classification, dietary sources, absorption, bioavailability, and metabolism of flavonoids.
  101. (2011). Clinical trials of resveratrol.
  102. (2008). Combination Chemoprevention of Intestinal Carcinogenesis in a Murine Model of Familial Adenomatous Polyposis.
  103. (2007). Compartmentalization of androgen receptor protein-protein interactions in living cells.
  104. (2006). Contemporary issues in prostate cancer: a nursing perspective,
  105. (2000). Corpse clearance defines the meaning of cell death.
  106. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
  107. (2003). Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review.
  108. (2001). Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
  109. (2005). Cycloxygeroase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer.
  110. (2002). Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US.
  111. (1998). Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial.
  112. (2005). Designing the selenium and vitamin E cancer prevention trial (SELECT).
  113. Detection of Apoptosis Based on the Interaction between Annexin V and Phosphatidylserine.
  114. (1997). Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.
  115. (2010). Determination of Quercetin and Resveratrol in Whole Blood-Implications for Bioavailability Studies.
  116. (2001). DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9.
  117. (1998). Diet, androgens, oxidative stress and prostate cancer susceptibility.
  118. (1998). Diet, nutrition, and prostate cancer.
  119. (2001). Dietary agents in cancer prevention: flavonoids and isoflavonoids.
  120. (1999). Dietary factors and risks for prostate cancer among blacks and whites in the United States.
  121. (1997). Dietary flavonoid and cancer prevention: Evidence and potential mechanism.
  122. (2010). Dietary Flavonoid Quercetin and Associated Health BenefitsAn Overview. Food Reviews
  123. (2005). Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP).
  124. (2000). Dietary intake and bioavailability of polyphenols.
  125. (2010). Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
  126. (2008). Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, DoubleBlind Trial.
  127. (1959). Discussion of cellular and humoral aspects of the hypersensitive states.
  128. (1975). Disposition of quercetin in man after single oral and intravenous doses.
  129. (2001). DNA content measurement for DNA ploidy and cell cycle analysis. Curr Protoc Cytom, Chapter 7,
  130. (2001). DNA measurement and cell cycle analysis by flow cytometry.
  131. (2004). Does finasteride alter the pathology of the prostate and cancer grading? Clinical prostate cancer,
  132. (1997). Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
  133. (2001). Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34(cdc2).
  134. (2010). Effect of Aging on DNA Excision/Synthesis Repair Capacities of Human Skin Fibroblasts.
  135. (2010). Effect of Dutasteride on the Risk of Prostate Cancer.
  136. (2006). Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
  137. (2002). Effect of flavonoids on cell cycle progression in prostate cancer cells.
  138. (1997). Effect of pH and ionic strength on the spectro-photometric assessment of nucleic acid purity.
  139. (2003). Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate.
  140. (2006). Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells.
  141. (2001). Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells.
  142. (1996). Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial -A randomized controlled trial.
  143. (2001). Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo.
  144. (2002). Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
  145. (2003). Endogenous sex hormones and prostate cancer risk: A case-control study nested within the carotene and retinol efficacy trial.
  146. (1999). Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies.
  147. (2010). Enhanced Stability and Intracellular Accumulation of Quercetin by Protection of the Chemically or Metabolically Susceptible Hydroxyl Groups with a Pivaloxymethyl (POM) Promoiety.
  148. (2010). Enhanced tumor suppression in vitro and in vivo by co-expression of survivinspecific siRNA and wild-type p53 protein.
  149. (2007). Epidemiology and pathophysiology of prostate cancer in AfricanAmerican men.
  150. (2003). ErbB1 and prostate cancer: ErbB1 activity is essential for androgeninduced proliferation and protection from the apoptotic effects of LY294002.
  151. (2006). Evidence for a biopsy derived grade artifact among larger prostate glands.
  152. (2007). Expression of androgen receptor is negatively regulated by p53.
  153. (2002). Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
  154. (1999). Family history and prostate cancer risk in a population-based cohort of Iowa men.
  155. (2000). Family history and the risk of prostate cancer.
  156. (1998). Family history of breast cancer as a predictor for fatal prostate cancer.
  157. (2005). Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia.
  158. (2007). Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
  159. (2011). Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: Implications for chemoprevention of prostate cancer.
  160. (2008). Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells.
  161. (2009). Flavones as Colorectal Cancer Chemopreventive Agents-Phenol-O-Methylation Enhances Efficacy.
  162. (2010). Flavonoid binding to human serum albumin.
  163. (2005). Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer.
  164. (2002). Flavonoids and steroid hormone-dependent cancers.
  165. (2000). Flavonoids suppress androgen-independent human prostate tumor proliferation.
  166. (2008). Flavonoids-induced accumulation of hypoxiainducible factor (HIF)-1 alpha/2 alpha is mediated through chelation of iron.
  167. (2001). Flavonoids: Structural requirements for antiproliferative activity on breast cancer cells.
  168. (1998). Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding.
  169. (1998). Functional activities of the A and B forms of the human androgen receptor in response to androgen receptor agonists and antagonists.
  170. (1999). Genetic predisposition, environment and cancer incidence: A nationwide twin study in Finland,
  171. (2008). Genetically engineered mouse models of prostate cancer.
  172. (2005). Genotoxicity of phytoestrogens.
  173. (1999). Global cancer statistics.
  174. (2002). Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes.
  175. (2010). Green Tea Flavan-3-ols: Colonic Degradation and Urinary Excretion of Catabolites by Humans.
  176. (2004). High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study.
  177. (2000). Hormonal predictors of prostate cancer: A meta-analysis.
  178. (2001). Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.
  179. (2008). Hormone-refractory prostate cancer: a primer for the primary care physician.
  180. (2000). Human metabolic pathways of dietary flavonoids and cinnamates.
  181. (2004). Human prostate cancer risk factors.
  182. (2003). Human red blood cells as a natural flavonoid reservoir.
  183. (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
  184. (2009). Identification and characterisation of 3’, 4’, 5’-Trimethoxyflavonol (TMFol) as a novel prostate chemoprevention agent. The 2nd academic symposium of Libyan students of the UK,
  185. (2004). Implementation of the prostate cancer prevention trial (PCPT).
  186. (1998). In vitro biotransformation of flavonoids by rat liver microsomes.
  187. (2004). In vitro drug metabolite profiling using hepatic S9 and human Liver Microsomes. In:
  188. (2005). In vitro metabolism of anthocyanins by human gut microflora.
  189. (2005). In vivo and in vitro effect of baicalein on human prostate cancer cells.
  190. (2009). Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
  191. (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
  192. (2004). Increased incidence of pathological and clinical prostate cancer with age: Age related alterations of local immune surveillance.
  193. (2005). Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity.
  194. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
  195. (2006). Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2).
  196. (2003). Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation.
  197. (2004). Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines.
  198. (2004). Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes.
  199. (2003). Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression.
  200. (2011). Insulin-Like Growth Factor System and Sporadic Malignant Melanoma.
  201. (2006). Integrative biology of prostate cancer progression.
  202. (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
  203. (1997). Intestinal uptake and biliary excretion of the isoflavone genistein in rats.
  204. (2003). Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites.
  205. (2003). Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence.
  206. (2005). Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
  207. (2003). Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?
  208. (2000). Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin.
  209. (2010). Karen Brown and Stewart Sale TMFol a novel prostate cancer chemopreventive agent: in vivo and in vitro efficacy study in prostate cancer models. The 3nd academic symposium of Libyan students of the UK,
  210. (2006). Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells.
  211. (1998). Lessons from basic research in selenium and cancer prevention.
  212. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals,
  213. (1998). Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma.
  214. (1997). Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
  215. (1998). Low P27 expression predicts poor disease-free survival in patients with prostate cancer.
  216. (2009). Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Molecular Cancer Therapeutics,
  217. (1997). Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines.
  218. (2009). Mechanisms mediating androgen receptor reactivation after castration.
  219. (2006). Mechanisms of action of novel agents for prostate cancer chemoprevention.
  220. (2006). Mechanisms of Disease: the role of heat-shock protein 90 in genitourinary malignancy.
  221. (2005). Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality.
  222. (2007). Metabolism and bioavailability of flavonoids in chemoprevention: Current analytical strategies and future prospectus.
  223. (2009). Metabolism and Pharmacokinetics of 3,3 ',4 ',7-Tetrahydroxyflavone (Fisetin), 5-Hydroxyflavone, and 7-Hydroxyflavone and Antihemolysis Effects of Fisetin and Its Serum Metabolites.
  224. (1996). Metastatic prostate cancer in a transgenic mouse.
  225. (2007). Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?
  226. (2004). Methyl selenium-induced vascular endothelial apoptosis is executed by caspases and principally mediated by P38 MAPK pathway.
  227. (2006). Methylated flavonoids have greatly improved intestinal absorption and metabolic stability.
  228. (2007). Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption.
  229. (2009). Methylation of Dietary Flavones Increases Their Metabolic Stability and Chemopreventive Effects.
  230. (2006). Methylation protects dietary flavonoids from rapid hepatic metabolism.
  231. (2005). Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
  232. (2010). Mitochondrial signaling in cell death via the Bcl-2 family.
  233. (1998). Model systems of prostate cancer: Uses and limitations.
  234. (2010). Modeling prostate cancer: a perspective on transgenic mouse models.
  235. (2006). Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells.
  236. (2004). Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells.
  237. (2005). Modulation of apoptosis by cancer chemopreventive agents. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis,
  238. (2006). Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2. Cancer Letters,
  239. (2009). Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
  240. (2006). Molecular biology of prostate-cancer pathogenesis.
  241. (2010). Molecular cell biology of androgen receptor signalling.
  242. (2009). Molecular mechanisms of castration-resistant prostate cancer progression.
  243. (2006). Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft.
  244. (2006). Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
  245. (1999). Mouse models of prostate cancer.
  246. (2002). Mouse models of prostate carcinogenesis.
  247. (1985). Multiethnic studies of diet, nutrition, and cancer in Hawaii. Princess Takamatsu Symp,
  248. (2003). National comprehensive cancer network guidelines for the management of prostate cancer.
  249. (2011). Natural Innate and Adaptive Immunity to Cancer.
  250. (2005). Naturally occurring dietary flavonoids cause profound cell cycle arrest, and alterations in cell cycle regulatory proteins in prostate cancer cells in vitro.
  251. (2003). New anticancer therapeutic targets in the cell cycle and cell cycle checkpoints.
  252. (1995). New diagnostic applications and physiological functions of prostate specific antigen.
  253. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway.
  254. (2000). New roles for Src kinases in control of cell survival and angiogenesis.
  255. (2005). New strategies for the medical treatment of prostate cancer.
  256. (2006). Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis,
  257. (2010). Novel targets for prostate cancer chemoprevention.
  258. (1996). Nutrition and prostate cancer.
  259. (2007). Obesity and prostate cancer: epidemiology and clinical implications.
  260. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
  261. (2010). Of Mice and Humans: Are They the Same?-Implications in Cancer Translational Research.
  262. (2010). Oral bioavailability of quercetin from different quercetin glycosides in dogs.
  263. (2004). Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells.
  264. (1996). Oxidative stress, caloric restriction, and aging.
  265. (2004). P27 deficiency accelerates progression of prostate cancer initiated by SV40 large T antigen.
  266. (1999). P27(kip1): A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.
  267. (2007). p27(kip1): a target for tumor therapies?
  268. (2003). p53 is required for 1,25-dihydroxyvitamin D-3-induced G(0) arrest but is not required for G(1) accumulation or apoptosis of LNCaP prostate cancer cells.
  269. (1999). Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen.
  270. (2003). Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.
  271. (2003). Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer.
  272. (2009). PCPT: Evidence That Finasteride Reduces Risk of Most Frequently Detected Intermediate-
  273. (2008). Penta-1,2,3,4,6-O-galloyl- beta -D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo.
  274. (2001). Pharmacokinetics and bioavailability of quercetin glycosides in humans.
  275. (2004). Pharmacokinetics and metabolism of dietary flavonoids in humans.
  276. (2000). Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers.
  277. (2001). Physical activity and risk of cancer in middle-aged men.
  278. (2004). Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro.
  279. (2000). Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis.
  280. (1999). Pleiotropic cell-division defects and apoptosis induced by interference with survivin function.
  281. (2007). Polyphenols and cancer cell growth.
  282. (2003). Prevention of prostate cancer with finasteride: US/European perspective.
  283. (2008). Prevention of prostate cancer: what we know and where we are going.
  284. Principles and practice of oncology, 5th edition,
  285. (2001). Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death.
  286. (2007). Programs for cell death - Apoptosis is only one way to go.
  287. (2001). Progress in prostate cancer chemoprevention: Modulators of promotion and progression.
  288. (1996). Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma.
  289. (2005). Prospective studies of dairy product and calcium intakes and prostate cancer risk: A meta-analysis.
  290. Prospective study of sex hormone levels and risk of prostate cancer.
  291. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigenpositive prostate cancer cells.
  292. (1998). Prostate cancer and supplementation with alphatocopherol and beta-carotene: Incidence and mortality in a controlled trial.
  293. (2011). Prostate Cancer and Vitamin D: What Does the Evidence Really Suggest? Urologic Clinics of
  294. (2010). Prostate Cancer Chemoprevention Strategies.
  295. (2007). Prostate cancer chemoprevention: Current status and future prospects.
  296. (2004). Prostate cancer chemoprevention: Models, limitations and potential (Review).
  297. (2008). Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice.
  298. (2006). Prostate cancer epidemiology.
  299. (2010). Prostate cancer prevention: concepts and clinical recommendations.
  300. (2005). Prostate cancer: Science and clinical practice.
  301. (2004). Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee.
  302. (2000). Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.
  303. (2003). Prostatespecific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
  304. (2000). Prostatic intraepithelial neoplasia.
  305. (2010). PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer.
  306. (2008). PSA and hK2 in the diagnosis of prostate cancer.
  307. (1999). PSA decline is an independent prognostic marker in hormonally treated prostate cancer.
  308. (2001). Pten and p27(KIP1) cooperate in prostate cancer tumor suppression in the mouse.
  309. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.
  310. (1996). Purification methods of mammalian catechol-Omethyltransferases.
  311. (2000). Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer.
  312. (2010). Quercetin Aglycone Is Bioavailable in Murine Pancreas and Pancreatic Xenografts.
  313. (2008). Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway.
  314. (2006). Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: A possible mediation by IGFBP-3.
  315. (2001). Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.
  316. (2010). Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3).
  317. (2005). Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
  318. Radical prostatectomy versus watchful waiting in early prostate cancer.
  319. (1999). Rapid signalling by androgen receptor in prostate cancer cells.
  320. (2006). Reactive oxygen species: role in the development of cancer and various chronic conditions.
  321. (2011). Recent role of inflammation in prostate diseases: chemoprevention development opportunity.
  322. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifenquercetin treatment is associated with inhibition of angiogenesis and cellular proliferation.
  323. (2004). Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation.
  324. (2003). Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT.
  325. (2005). Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation.
  326. (2001). Regulation of apoptosis in prostate cancer.
  327. (2001). Regulation of cell cycle checkpoints in mammalian cells.
  328. (2005). Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.
  329. (2008). Relationship between the methylation status of dietary flavonoids and their growth-inhibitory and apoptosis-inducing activities in human cancer cells.
  330. (2001). Results of prostate cancer screening in non symptomatic men.
  331. (1999). Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.
  332. (2007). Resveratrol suppresses prostate cancer progression in transgenic mice.
  333. (2007). Reviving the acid phosphatase test for prostate cancer.
  334. (1999). Risk factors for prostate carcinoma in Taiwan - A case-control study in a Chinese population.
  335. (1994). Role of androgens in prostatic cancer.
  336. (2008). Role of Bax in quercetin-induced apoptosis in human prostate cancer cells.
  337. (2000). Role of diet modification in cancer prevention.
  338. (2008). Role of hormonal and other factors in human prostate cancer.
  339. (1998). Role of p27 in prostate carcinogenesis.
  340. (2010). Roles of androgen receptor in male and female reproduction: lessons from global and cell-specific androgen receptor knockout (ARKO) mice.
  341. (2002). Roles of androgens in the development, growth, and carcinogenesis of the mammary gland.
  342. (2002). Science, medicine, and the future - Cancer chemoprevention.
  343. (2004). Selenium: Epidemiology and basic science.
  344. (2009). Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.
  345. (2009). Smoking and aggressive prostate cancer: a review of the epidemiologic evidence.
  346. (2001). Smoking and prostate cancer.
  347. (2009). Soy Food Consumption and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies.
  348. (2000). Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.
  349. (1999). Strategies for chemoprevention of prostate cancer.
  350. (2008). Structural basis for the nuclear import of the human androgen receptor.
  351. (2002). Structureactivity relationships for inhibition of human 5 alpha-reductases by polyphenols.
  352. (2010). Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins
  353. (1941). Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. cancer research,
  354. (2010). Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells.
  355. (2010). Survivin and IAP proteins in cell-death mechanisms.
  356. (2004). Survivin expression is associated with features of biologically aggressive prostate carcinoma.
  357. (2005). Survivin mediates resistance to antiandrogen therapy in prostate cancer.
  358. (2007). Survivin: A promising tumor biomarker.
  359. (2009). Synthesis of the flavonoid 3 ',4 ',5 '-trimethoxyflavonol and its determination in plasma and tissues of mice by HPLC with fluorescence detection.
  360. (2011). Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells.
  361. (2003). Tea beverage in chemoprevention of prostate cancer: A mini-review.
  362. (2006). Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption.
  363. (2005). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
  364. (2004). The androgen receptor gene mutations database (ARDB):
  365. (2011). The antigenotoxic effects of grapefruit juice on the damage induced by benzo(a)pyrene and evaluation of its interaction with hepatic and intestinal Cytochrome P450 (Cyp)1a1. Food and Chemical Toxicology,
  366. (1997). The antiovulatory effect of the antiprogestin onapristone could be related to down-regulation of intraovarian progesterone (receptors).
  367. (2007). The Bcl-2 apoptotic switch in cancer development and therapy.
  368. (2000). The biochemistry of apoptosis.
  369. (2004). The complex genetic epidemiology of prostate cancer.
  370. (2008). The current state of preclinical prostate cancer animal models.
  371. (2003). The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.
  372. (2001). The development of androgen-independent prostate cancer.
  373. (2008). The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by downregulating the expression of heat shock protein 90.
  374. (1980). The Dunning tumors.
  375. (2000). The EGF receptor family as targets for cancer therapy.
  376. (2010). The EGFR/HER2-elicited multiple pathways in development, progression, and theragnosis of prostate cancer.
  377. (1998). The epidemiology of prostate cancer in Jamaica.
  378. (2005). The epidemiology of vitamin D and cancer incidence and mortality: A review (United States).
  379. (2002). The evolving role of estrogen therapy in prostate cancer.
  380. (2011). The evolving role of familial history for prostate cancer.
  381. (1976). The flavonoids. A class of semi-essential food components: their role in human nutrition.
  382. (2009). The function of p27 KIP1 during tumor development.
  383. (2006). The Human PC346 Xenograft and Cell Line Panel: A Model System for Prostate Cancer Progression.
  384. (1999). The immune system as anti-tumor sentinel: Molecular requirements for an anti-tumor immune response. Critical Reviews in Oncogenesis,
  385. (1999). The immune system in the elderly II. Specific cellular immunity.
  386. (1999). The immune system in the elderly III. Innate immunity.
  387. (2010). The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach.
  388. (1997). The importance of sodium pyruvate in assessing damage produced by hydrogen peroxide.
  389. (2003). The influence of finasteride on the development of prostate cancer.
  390. (2000). The Ki-67 protein: From the known and the unknown.
  391. (1980). The LNCaP cell line--a new model for studies on human prostatic carcinoma.
  392. (2001). The machinery of programmed cell death.
  393. (2006). The p53 tumor suppressor participates in multiple cell cycle checkpoints.
  394. (2000). The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: A proposal to modify the Gleason grading system.
  395. (1997). The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis.
  396. (2008). The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
  397. (2008). The role of DNA damage and repair in aging: New approaches to an old problem.
  398. (2004). The role of inflammation in the pathogenesis of prostate cancer.
  399. (2003). The role of vitamin D in prostate cancer. Recent Results Cancer Res,
  400. (1999). The small intestine can both absorb and glucuronidate luminal flavonoids.
  401. (2005). The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions.
  402. (2010). The Use of Animal Models for Cancer Chemoprevention Drug Development. Seminars in
  403. (2005). The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutation ResearchFundamental and Molecular Mechanisms of Mutagenesis,
  404. (2009). Tissue distribution in mice following a single oral dose.
  405. (2009). Tissue distribution in mice following a single oral dose. The 2nd academic symposium of Libyan students of the UK,
  406. (2007). Tissue distribution of lignans in rats in response to diet, dose-response, and competition with isoflavones.
  407. (2005). Tissue distribution of quercetin in rats and pigs.
  408. (2003). Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase.
  409. (2007). TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
  410. (1999). Transcriptional analysis of human survivin gene expression.
  411. (1998). Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol).
  412. (2000). Treatment of prostate cancer: Watchful waiting, radical prostatectomy, and cryoablation.
  413. (2001). Trends and patterns of prostate cancer: What do they suggest?
  414. (2006). Tumor models for efficacy determination.
  415. (2007). Twenty Years of PSA: From Prostate Antigen to Tumor Marker.
  416. (2005). Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice.
  417. (2010). Update on chemoprevention for prostate cancer.
  418. (1999). Use of animal models in defining efficacy of chemoprevention agents against prostate cancer.
  419. (2009). Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy.
  420. (2005). Vitamin E not helpful, perhaps harmful.
  421. (2003). Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery.
  422. (1998). Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.